Amarin Corp. PLC (AMRN) Stock Price Up 5.2%
Amarin Corp. PLC (NASDAQ:AMRN) shares rose 5.2% on Friday . The stock traded as high as $3.32 and last traded at $3.25, with a volume of 2,355,318 shares traded. The stock had previously closed at $3.09.
AMRN has been the topic of several recent research reports. Zacks Investment Research upgraded Amarin Corp. PLC from a “sell” rating to a “hold” rating in a research report on Tuesday, April 26th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Amarin Corp. PLC in a research report on Monday, May 9th. Finally, Jefferies Group initiated coverage on Amarin Corp. PLC in a research report on Thursday, May 12th. They set a “buy” rating and a $3.50 price objective on the stock.
The company’s market cap is $588.72 million. The company has a 50-day moving average price of $2.63 and a 200 day moving average price of $1.94.
Amarin Corp. PLC (NASDAQ:AMRN) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.13) by $0.06. The company had revenue of $32.82 million for the quarter, compared to analysts’ expectations of $29.97 million. The firm’s quarterly revenue was up 85.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.15) EPS. On average, equities analysts expect that Amarin Corp. PLC will post ($0.46) EPS for the current fiscal year.
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.